Bessac; Laurence

Patent Applications and Registrations

Patent applications and USPTO patent grants for Bessac; Laurence.The latest application filed is for "human antibodies to pcsk9 for use in methods of treating particular groups of subjects".

Company Profile

8.8.21

Bessac; Laurence - Paris FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Human Antibodies To Pcsk9 For Use In Methods Of Treating Particular Groups Of Subjects App 20220218823 - Hanotin; Corinne ; et al.	2022-07-14
Methods For Reducing Cardiovascular Risk App 20220144969 - Bessac; Laurence ; et al.	2022-05-12
Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody Grant 11,306,155 - Baccara-Dinet , et al. April 19, 2	2022-04-19
Human antibodies to PCSK9 for use in methods of treating particular groups of subjects Grant 11,246,925 - Hanotin , et al. February 15, 2	2022-02-15
Methods For Treating High Cardiovascular Risk Patients With Hypercholesterolemia App 20200255544 - Kind Code	2020-08-13
METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH) WITH AN ANTI-PCSK9 ANTIBODY App 20200216565 - Baccara-Dinet; Marie ; et al.	2020-07-09
Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody Grant 10,544,232 - Baccara-Dinet , et al. Ja	2020-01-28
Dosing Regimens For Use With Pcsk9 Inhibitors App 20200024364 - Baccara-Dinet; Marie ; et al.	2020-01-23
Human Antibodies To Pcsk9 For Use In Methods Of Treating Particular Groups Of Subjects App 20190343719 - Hanotin; Corinne ; et al.	2019-11-14
Dosing regimens for use with PCSK9 inhibitors Grant 10,428,157 - Baccara-Dinet , et al. October 1, 2	2019-10-01
Methods For Reducing Cardiovascular Risk App 20190292273 - Hanotin; Corinne ; et al.	2019-09-26
Methods for Treating Patients with Hypercholesterolemia that is not Adequately Controlled by Moderate-Dose Statin Therapy App 20180296672 - Pordy; Robert C. ; et al.	2018-10-18
Pharmaceutical Compositions Comprising Human Antibodies To Pcsk9 App 20170340515 - HANOTIN; Corinne ; et al.	2017-11-30
Human Antibodies To Pcsk9 For Use In Methods Of Treating Particular Groups Of Subjects App 20170266079 - Hanotin; Corinne ; et al.	2017-09-21
Pharmaceutical compositions comprising human antibodies to PCSK9 Grant 9,682,013 - Hanotin , et al. June 20, 2	2017-06-20
Method of reducing cholesterol levels using a human anti-PCSK9 antibody Grant 9,561,155 - Hanotin , et al. February 7, 2	2017-02-07
Methods For Treating High Cardiovascular Risk Patients With Hypercholesterolemia App 20160137746 - Hanotin; Corinne ; et al.	2016-05-19
METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH) App 20160137745 - Baccara-Dinet; Marie ; et al.	2016-05-19
Methods For Reducing Cardiovascular Risk App 20150284473 - Bessac; Laurence ; et al.	2015-10-08
Methods For Treating Patients With Hypercholesterolemia That Is Not Adequately Controlled By Moderate-dose Statin Therapy App 20150231236 - Pordy; Robert C. ; et al.	2015-08-20
Dosing Regimens For Use With Pcsk9 Inhibitors App 20150152191 - Baccara-Dinet; Marie ; et al.	2015-06-04
Use Of A Pcsk9 Inhibitor To Treat Hyperlipidemia App 20150140002 - Baccara-Dinet; Marie ; et al.	2015-05-21
Pharmaceutical Compositions Comprising Human Antibodies To Pcsk9 App 20140178402 - Hanotin; Corinne ; et al.	2014-06-26
Human Antibodies To Pcsk9 For Use In Methods Of Treating Particular Groups Of Subjects App 20140154262 - Hanotin; Corinne ; et al.	2014-06-05

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.